MedPath

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Phase 1
Recruiting
Conditions
High Grade Epithelial Ovarian Cancer
High Grade Serous Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Endometrial Cancer
Non-small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Mesothelioma
Breast Adenocarcinoma
Triple Negative Breast Cancer
Interventions
Registration Number
NCT05579366
Lead Sponsor
ProfoundBio US Co.
Brief Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Detailed Description

This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.

The study consists of multiple parts:

Part A: monotherapy cohorts

Part B: tumor-specific monotherapy dose-expansion cohorts

Part C: platinum-resistant ovarian cancer (PROC) cohort

Part D: combination therapy cohorts

Part F: a monotherapy endometrial cancer cohort

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
529
Inclusion Criteria

Part A and B:

  • Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma.
  • Previously received therapies known to confer clinical benefit.
  • Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.

Part C:

Participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.

  • High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)
  • Participants must have received 1 to 3 prior lines of therapy. Participants who had 1 to 4 prior lines of therapy are allowed if mirvetuximab soravtansine (MIRV) was the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
  • Participants must have platinum-resistant ovarian cancer.
  • Participants must have received prior bevacizumab.
  • Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration [FDA]-approved test in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
  • Participants must have known FRα status based on an FDA approved test. Those who are FRα positive must have previously received MIRV, unless the participant has a documented medical exception.
  • Participants who are FRα negative, in accordance with the FDA approved test (Ventana folate receptor [FOLR1] RxDx Assay), and were treated with MIRV, are excluded.
  • Measurable disease per the RECIST v1.1 at baseline.

Part D:

Cohort D1 (Rina-S+carboplatin):

  • Participants must have platinum-sensitive ovarian cancer.
  • Participants must have received 1 to 3 prior lines of therapy.

Cohort D2 (Rina-S+bevacizumab):

  • Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.

  • Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.

  • Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.

    • Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (>183 days) or more from the last dose of platinum-based therapy.

Cohort D3 (Rina-S+pembrolizumab):

  • Endometrial cancer (any subtype excluding sarcoma).
  • Participants must have received prior platinum-based chemotherapy for recurrent or advanced disease.

Part F:

  • Participants must have histologically or cytologically confirmed endometrial cancer as specified below.
  • Advanced, recurrent, metastatic, or primary unresectable endometrial cancer (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma)
  • Participants must have received 1 to 3 prior lines of therapy in advanced, recurrent, or metastatic setting, and must have progressed radiographically on or after their most recent line of therapy:
  • Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-[L])1 inhibitor.
  • Participants who progress >12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.
  • Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.
  • Measurable disease per the RECIST Version 1.1 at baseline.
Exclusion Criteria
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Use of a strong cytochrome P450 3A (CYP3A) inhibitor within 14 days (dose escalation only).
  • Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.

Note: Other protocol-defined inclusion/exclusion may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part A, B, C and FRina-SRina-S monotherapy in Part A and at the recommended dose in Parts B, C and F.
Part D1Rina-SRina-S in combination with carboplatin
Part D1CarboplatinRina-S in combination with carboplatin
Part D2Rina-SRina-S in combination with bevacizumab
Part D2BevacizumabRina-S in combination with bevacizumab
Part D3Rina-SRina-S in combination with pembrolizumab
Part D3PembrolizumabRina-S in combination with pembrolizumab
Primary Outcome Measures
NameTimeMethod
Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]Through end of treatment, up to approximately 1 year.
Parts A, and D - Dose Limiting Toxicity (DLT)At the end of Cycle 1 (each cycle is 21 days)

The proportion of participants experiencing DLT.

Parts C and F- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Through end of treatment, up to approximately 1 year.

Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.

Secondary Outcome Measures
NameTimeMethod
Parts A, B, and D - Best Overall Response (BOR)Up to approximately 1 year.

Participants who achieve CR or PR. Best response as assessed by the investigator per RECIST v1.1 criteria for all tumor types other than pleural mesothelioma which will use modified RECIST (mRECIST) v1.1.

Parts A, B, and D - ORRUp to approximately 1 year.

Participants who achieve PR or CR per RECIST v1.1 criteria.

Parts A, B, and D - Disease Control Rate (DCR)Up to approximately 1 year.

Participants who achieve stable disease, PR or CR per RECIST v1.1 criteria.

Parts A, B, C, D and F - Progression-Free Survival (PFS)Through end of treatment, up to approximately 1 year.

Time from start of treatment to first documented disease progression or death

Parts C and F - Overall survival (OS)Up to approximately 2 years.

Time from the start of study treatment to the date of death from any cause

Parts A, B, C, D and F - Duration of Objective Response (DOR)From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.

Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death

Parts A, B, and D - Peak Plasma Concentration (Cmax) for Rina-SThrough end of treatment, up to approximately 1 year.

Measurement of maximum plasma concentration after the administration of Rina-S.

Parts A, B, and D - Area Under the Plasma Concentration Versus Time Curve (AUC) for Rina-SThrough end of treatment, up to approximately 1 year.

Measurement of AUC after the administration of Rina-S.

Parts A, B, and D -Time to Reach Cmax (Tmax) for Rina-SThrough end of treatment, up to approximately 1 year
Parts A, B, and D - Trough Concentrations (Ctrough) for Rina-SThrough end of treatment, up to approximately 1 year
Parts A, B, and D - Apparent Terminal Half-life (t1/2) for Rina-SThrough end of treatment, up to approximately 1 year
Parts C and D - CA-125 Response Determined Using the Gynecologic Cancer Intergroup (GCIG) CriteriaThrough end of treatment, up to approximately 1 year
Parts C and F - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)Through end of treatment, up to approximately 1 year

Trial Locations

Locations (36)

University of California Los Angeles Medical Center

🇺🇸

Los Angeles, California, United States

USOR HonorHealth

🇺🇸

Phoenix, Arizona, United States

USOR Arizona Oncology Associates

🇺🇸

Tucson, Arizona, United States

University of California, San Diego; Moores Cancer Center

🇺🇸

San Diego, California, United States

USOR Sansum Clinic

🇺🇸

Santa Barbara, California, United States

Providence Medical Foundation

🇺🇸

Santa Rosa, California, United States

USOR Florida Cancer Specialists South

🇺🇸

Fort Myers, Florida, United States

USOR Florida Cancer Specialists North

🇺🇸

Saint Petersburg, Florida, United States

USOR Florida Cancer Specialists East

🇺🇸

West Palm Beach, Florida, United States

University of Kansas Medical Center (KUMC)

🇺🇸

Westwood, Kansas, United States

USOR Maryland Oncology Hematology

🇺🇸

Rockville, Maryland, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Dana Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

START Midwest

🇺🇸

Grand Rapids, Michigan, United States

USOR Minnesota Oncology Hematology

🇺🇸

Maplewood, Minnesota, United States

University of Oklahoma - Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

USOR Oncology Associates of Oregon, P.C.

🇺🇸

Eugene, Oregon, United States

Compass Oncology - Rose Quarter

🇺🇸

Portland, Oregon, United States

USOR Alliance Cancer Specialist

🇺🇸

Doylestown, Pennsylvania, United States

Women and Infants Hospital of Rhode Island

🇺🇸

Providence, Rhode Island, United States

Sarah Cannon Research Institute at Tennessee Oncology

🇺🇸

Nashville, Tennessee, United States

USOR Texas Oncology

🇺🇸

Fort Worth, Texas, United States

Texas Oncology - Central / South Texas

🇺🇸

Austin, Texas, United States

Mary Crowley Cancer Research

🇺🇸

Dallas, Texas, United States

Texas Oncology - Northeast TX

🇺🇸

Tyler, Texas, United States

USOR Texas Oncology Gulf Coast

🇺🇸

Woodland, Texas, United States

START Mountain Region

🇺🇸

West Valley City, Utah, United States

USOR Virginia Cancer Specialists

🇺🇸

Fairfax, Virginia, United States

USOR Virginia Oncology Associates

🇺🇸

Norfolk, Virginia, United States

Cancer hospital, Chinese Academy of Medical Sciences

🇨🇳

Beijing, Beijing, China

Hunan Cancer Hospital - Phase 1

🇨🇳

Changsha, Hunan, China

Jilin Cancer Hospital

🇨🇳

Chang chun, Jilin, China

Fudan University Shanghai Cancer Center - Gynecologic Oncology

🇨🇳

Shanghai, Shanghai, China

Hunan Cancer Hospital - Thoracic Medicine Dept II

🇨🇳

Changsha, Hunan, China

Fudan University Shanghai Cancer Center- Phase 1

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath